Renal cell carcinoma: Resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins

Medical Hypotheses

Volumn 78, Issue 2, 2012, Pages 330-336

  Rajandram, R ^a,b   Bennett, N C ^a   Morais, C ^a   Johnson, D W ^a,c   Gobe, G C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CASPASE 3; CASPASE 8; CISPLATIN; EVEROLIMUS; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CELL VIABILITY; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

APOPTOSIS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 84855201584     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.11.014     Document Type: Article

References (81)

1. Miyake H., Gleave M.E., Arakawa S., Kamidono S., Hara I. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol 2002, 167:2203-2208.
2. Amato R.J. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005, 16:7-15.
3. Gupta K., Miller J.D., Li J.Z., Russell M.W., Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205.
4. Nicol D. Issues in the diagnosis of renal cell carcinoma. BJU Int 2000, 86:298-303.
5. Tang S.W., Chang W.H., Chao Y.W., Lin C.Y., Chen H.F., Lai Y.H., et al. Identification of differentially expressed genes in clear cell renal cell carcinoma by analysis of full-length enriched cDNA library. J Biomed Sci 2006, 13:233-240.
6. Bortner C.D., Cidlowski J.A. Cellular mechanisms for the repression of apoptosis. Annu Rev Pharmacol Toxicol 2002, 42:259-281.
7. Berger A., Kamoi K., Gill I.S., Aron M. Cryoablation for renal tumors: current status. Curr Opin Urol 2009, 19:138-142.
8. Longo R., D'Andrea M.R., Sarmiento R., Salerno F., Gasparini G. Integrated therapy of kidney cancer. Ann Oncol 2007, 18(Suppl. 6):141-148.
9. Reed J.C., Doctor K., Rojas A., Zapata J.M., Stehlik C., Fiorentino L., et al. Comparative analysis of apoptosis and inflammation genes of mice and humans. Genome Res 2003, 13:1376-1388.
10. N.H. Ruddle, Roles of the TNF family in normal development and cancer, Adv Exp Med Biol 2011. DOI doi:10.1007/978-1-4419-6612-4_1.
11. Hughes P.D., Belz G.T., Fortner K.A., Budd R.C., Strasser A., Bouillet P. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 2008, 28:197-205.
12. Ashe P.C., Berry M.D. Apoptotic signaling cascades. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(27):199-214.
13. Zörnig M., Hueber A.-O., Baum W., Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001, 1551:F1-F37.
14. Zapata J.M., Krajewska M., Morse H.C., Choi Y., Reed J.C. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 2004, 101:16600-16605.
15. Zapata J.M. TNF-receptor-associated factors as targets for drug development. Expert Opin Ther Targets 2003, 7(7):411-425.
16. Harrison M.L., Obermueller E., Maisey N.R., Hoare S., Edmonds K., Li N.F., et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007, 25:4542-4549.
17. Xanthoulea S., Pasparakis M., Kousteni S., Brakebusch C., Wallach D., Bauer J., et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004, 200:367-376.
18. Tsitsikov E.N., Laouini D., Dunn I.F., Sannikova T.Y., Davidson L., Alt F.W., et al. TRAF1 is a negative regulator of TNF signaling. Enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001, 15:647-657.
19. Bradley J.R., Pober J.S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001, 20:6482-6491.
20. Godley P., Kim S.W. Renal cell carcinoma. Curr Opin Oncol 2002, 14:280-285.
21. World Health Organisation Pathology & Genetics: Tumours of the Urinary System and Male Genital Organs 2004, 12-31. IARC Press, Lyon. J.N. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn (Eds.).
22. Kim J.H., Jung C.W., Cho Y.H., Lee J., Lee S.H., Kim H.Y., et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005, 13:859-864.
23. Nyhan M.H., O'Sullivan G.C., McKenna S.L. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans 2008, 36:472-478.
24. Nagashima Y., Inayama Y., Kato Y., Sakai N., Kanno H., Aoki I., et al. Pathological and molecular biological aspects of the renal epithelial neoplasms, up-to-date. Pathol Int 2004, 54:377-386.
25. Beck S.D., Patel M.I., Snyder M.E., Kattan M.J., Motzer R.J., Reuter V.E., et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004, 11:71-77.
26. Takahashi M., Sugimura J., Yang X., Vogelzang N., The B.S., Furge K., et al. Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Adv Cancer Res 2003, 89:157-181.
27. Tickoo S.K., dePeralta-Venturina M.N., Harik L.R., Worcester H.D., Salama M.E., Young A.N. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 2006, 30:141-153.
28. Bodmer D., van den Hurk W., van Groningen J.J., Eleveld M.J., Martens G.J., Weterman M.A., et al. Understanding familial and non-familial renal cell cancer. Hum Mol Genet 2002, 11:2489-2498.
29. Chao D., Zisman A., Pantuck A.J., Gitlitz B.J., Freedland S.J., Said J.W., et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 2002, 167:71-74.
30. Takahashi M., Yang X.M.J., Sugimura J., Backdahl J., Tretiakova M., Qian C.N., et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003, 22:6810-6818.
31. Zisman A., Chao D.H., Pantuck A.J., Kim H.J., Wieder J.A., Figlin R.A., et al. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol 2002, 168:950-955.
32. Cangiano T., Liao J., Dorey F., Figlin R., Belldegrun A. Sarcomatoid renal cell carcinoma: Biologic behavious, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999, 17:523-528.
33. Gong Y., Sun X., Haines G.K., Pins M.R. Renal cell carcinoma, chromophobe type, with collecting duct carcinoma and sarcomatoid components. Arch Pathol Lab Med 2003, 127:e38-e40.
34. Mathers M.E., Pollock A.M., Marsh C., O'Donnell M. Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology 2002, 49:563-567.
35. Amin M.B., Crotty T.B., Tickoo S.K., Farrow G.M. Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol 1997, 21:1-12.
36. Lin P.Y., Fosmire S.P., Park J.Y., Baksh S., Modiano J.F., Weiss R.H. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: A potential mechanism of apoptosis resistance. Mol Cancer 2007, 6:16-27.
37. Hager M., Haufe H., Kemmerling R., Hitzl W., Mikuz G., Moser P.L., et al. Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 2009, 11:2181-2188.
38. Brugarolas J., Lotan Y., Watumull L., Kabbani W. Sirolimus in metatastic renal cell carcinoma. J Clin Oncol 2008, 26:3457-3460.
39. Rini B., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10:992-1000.
40. Scheltema J.M., Romijn J.C., Van Steenbrugge G.J., Schroder F.H., Mickisch G.H. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells. Anticancer Res 2001, 21:3161-3166.
41. Lucci A., Han T.Y., Liu Y.Y., Giuliano A.E., Cabot M.C. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 1999, 86:300-311.
42. Yamamoto K., Mizutani Y., Nakanishi H., Fujiwara J., Ishida H., Toiyama D., et al. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma. Int J Oncol 2008, 33:565-571.
43. Bleumer I., Oosterwijk E., De Mulder P., Mulders P.F.A. Immunotherapy for renal cell carcinoma. Eur Urol 2003, 44:65-75.
44. Halperin E.C., Harisiadis L. The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 1983, 51:614-617.
45. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7:97-110.
46. Mizutani Y., Nakanishi H., Yoshida O., Fukushima M., Bonavida B., Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002, 38:167-176.
47. Alas S., Ng C.P., Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 2002, 8:836-845.
48. Nishisaka N., Jones R.F., Morse P., Kuratsukuri K., Romanowski R., Wang C.Y., et al. Inhibition of lung metastases of murine renal cell carcinoma by the combination of radiation and interferon-alpha-producing tumor cell vaccine. Cytokines Cell Mol Ther 2000, 6:199-206.
49. E. Herrmann, N. Marschner, M.O. Grimm, C.H. Ohlmann, H. Hutzschenreuter and F. Overkamp et al., Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma, World J Urol 2011; [Epub ahead of print].
50. Varuni Kondagunta G., Drucker B., Schwartz L., Bacik J., Marion S., Russo P., et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004, 18:3720-3725.
51. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
52. Desagher S., Martinou J.C. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000, 10:369-377.
53. Crompton M. Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr Opin Cell Biol 2000, 12:414-419.
54. Rossi D., Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003, 88:212-218.
55. Philchenkov A. Caspases: potential targets for regulating cell death. J Cell Mol Med 2004, 8:432-444.
56. Brooks A.D., Jacobsen K., Li W., Shanker A., Sayers T.J. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res 2010, 8:729-738.
57. Vasavada S.P., Novick A.C., Williams B.R. P53, bcl-2, And Bax expression in renal cell carcinoma. Urology 1998, 51:1057-1061.
58. Gobe G., Rubin M., Williams G., Sawczuk I., Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest 2002, 20:324-332.
59. Wu X.X., Kakehi Y., Mizutani Y., Lu J., Terachi T., Ogawa O. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 2001, 19:19-24.
60. Davidson K., Percy C., Rennick A.J., Pat B.K., Li J., Nicol D., et al. Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas. Nephron Exp Nephrol 2005, 99:112-120.
61. Chung J.Y., Park Y.C., Ye H., Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002, 115:679-688.
62. Zapata J.M., Matsuzawa S., Godzik A., Leo E., Wasserman S.A., Reed J.C. The Drosophila tumor necrosis factor receptor-associated factor-1 (DTRAF1) interacts with Pelle and regulates NFkappaB activity. J Biol Chem 2000, 275:12102-12107.
63. Jang H.D., Chung Y.M., Baik J.H., Choi Y.G., Park I.S., Jung Y.K. Caspase-cleaved TRAF1 negatively regulates the antiapoptotic signals of TRAF2 during TNF-induced cell death. Biochem Biophys Res Commun 2001, 281:499-505.
64. Zhang B., Wang Z., Li T., Tsitsikov E.N., Ding H.F. NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 2007, 110:743-751.70.
65. Wang X., Wang Q., Hu W., Evers B.M. Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway. Oncogene 2004, 23:1885-1895.
66. Blackwell K., Zhang L., Thomas G.S., Sun H., Nakano H., Habelhah H. TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis. Mol Cell Biol 2009, 29:303-314.
67. Zhang L., Blackwell K., Shi Z., Habelhah H. The RING domain of TRAF2 plays an essential role in the inhibition of TNFalpha-induced cell death but not in the activation of NF-kappaB. J Mol Biol 2010, 396:528-539.
68. Morais C., Gobe G., Johnson D.W., Healy H.H. The emerging role of nuclear factor kappa B in renal cell carcinoma. Int J Biochem Cell Biol 2011, 43:1537-1549.
69. Morais C., Healy H., Johnson D.W., Gobe G. Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma. Nephrol Dial Transplant 2010, 25:1462-1474.
70. Rajandram R., Pat B.K., Li J., Johnson D.W., Gobe G.C. Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma. Nephrology (Carlton) 2009, 14:205-212.
71. Bellail A.C., Qi L., Mulligan P., Chhabra V., Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009, 4:34-41.
72. Sayers T.J. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 2011, 60:1173-1180.
73. Khanbolooki S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., et al. Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006, 5:2251-2260.
74. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, Progression and therapy. Nat Rev Cancer 2008, 8:782-798.
75. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations. Nature Biotechnol 1998, 16:153-157.
76. Garcia A.E., Camarero J.A. Biological activities of natural and engineered cyclotides, a novel molecular for peptide-based therapies. Curr Mol Pharmacol 2010, 3:153-163.
77. Duffy M.J. Predictive markers in breast and other cancers: a review. Clin Chem 2005, 51:494-503.
78. Gasparini G., Longo R., Torino F., Gattuso D., Morabito A., Toffoli G. Is tailored therapy feasible in oncology?. Crit Rev Oncol Hematol 2006, 57:79-101.
79. Ather M.H., Masood N., Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urol J 2010, 7:1-9.
80. Vermaat J.S., van der Tweel I., Mehra N., Sleijfer S., Haanen J.B., Roodhart J.M., et al. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 2010, 21:1472-1481.
81. Swanton C., Larkin J.M., Gerlinger M., Eklund A.C., Howell M., Stamp G., et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010, 2:53.